MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-100934-PIP01-23-M01

Scope of the Application

Active Substance(s)

CARFILZOMIB

Condition(s)

Treatment of acute lymphoblastic leukaemia

Pharmaceutical Form(s)

Powder for solution for infusion

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

Amgen Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Amgen Limited submitted to the licensing authority on 06/04/2023 09:28 BST an application for a Modification

The procedure started on 17/08/2023 15:14 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100934-PIP01-23-M01

Of 01/09/2023 07:57 BST

On the adopted decision for CARFILZOMIB (MHRA-100934-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for CARFILZOMIB, Powder for solution for infusion , INTRAVENOUS USE .

This decision is addressed to Amgen Limited, 216 Cambridge Science Park, Milton Road, Cambridge, UNITED KINGDOM, CB4 0WA

ANNEX I

1. Waiver

1.1 Condition:

Treatment of acute lymphoblastic leukaemia The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 month of age Pharmaceutical form(s): Powder for solution for infusion Route(s) of administration: INTRAVENOUS USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of acute lymphoblastic leukaemia

2.2 Indication(s) targeted by the PIP:

Treatment for paediatric patients with relapsed or refractory T-cell acute lymphoblastic leukaemia or paediatric patients with relapsed or refractory B-cell acute lymphoblastic leukaemia who received prior targeted immune therapy

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 1 month to less than 18 years of age

2.4 Pharmaceutical Form(s):

Powder for solution for infusion

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	1	Study 1 (20140106) Part 1 (phase 1b): uncontrolled, dose-escalation study in patients from 1 year to less than 18 years of age (and adults), with relapsed or refractory T-cell or B-cell acute lymphoblastic leukaemia with or without extramedullary disease, to assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, and to determine the optimal dose for the subsequent part 2 study of carfilzomib (CFZ) in combination with induction chemotherapy. Part 2 (phase 2): externally-controlled, single arm study of carfilzomib (CFZ) in combination with VXLD induction chemotherapy (vincristine, dexamethasone, PEG asparaginase, and daunorubicin) from 1 month to less than 18 years (diagnosis must be prior to 18 years) of age (and adults) with relapsed or refractory T-cell ALL or B-cell acute lymphoblastic leukaemia, who must have a bone marrow relapse with

		or without extramedullary disease after receiving a targeted B-cell immune therapy as treatment for a prior relapse, to compare the rate of complete remission (CR) at the end of induction therapy to an external control.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/01/2024
Deferral of one or more studies contained in the paediatric investigation plan:	Yes